VB
Vikas Bhardwaj
Medical Technologist, AIIMS New Delhi
Updated: Apr 17, 2026
**Core Concept**
The patient has a history of hypertension (HTN) and type 2 diabetes mellitus (T2DM) with poorly controlled blood pressure and blood sugar levels, leading to complications such as albuminuria. The use of calcium channel blockers (cA preparations, also known as calcium channel antagonists) is common in such patients. **Nephropathy** and **cardiovascular disease** are significant concerns in this scenario.
**Why the Correct Answer is Right**
Given the context, the correct answer would relate to a drug that could exacerbate the patient's condition, particularly in the context of renal function and blood pressure control. Drugs that are known to worsen renal function or interact negatively with cA preparations would be contraindicated.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option provided, it's challenging to address each incorrect choice directly. However, generally, any option that involves a drug known to be safe or even beneficial in the context of HTN, T2DM, and renal protection could be considered incorrect if it's labeled as the wrong choice.
**Option B:** Similarly, without specifics, one might infer that any drug not typically contraindicated in renal impairment or HTN could be an incorrect choice.
**Option C:** And again, lacking specifics, one could reason that a drug not known to interfere with cA preparations or worsen the patient's condition would not be the correct answer.
**Option D:** This would follow the same logic as the other options, needing the specific drug to assess its appropriateness.
**Clinical Pearl / High-Yield Fact**
In patients with a history of HTN and T2DM, especially those with signs of renal involvement like albuminuria, it's crucial to consider the potential effects of medications on renal function and blood pressure control. Certain drugs can exacerbate kidney disease or interact with common medications like cA preparations, necessitating careful selection of therapies.
**Correct Answer:** Correct Answer: D. Cyclosporin